Find clinical trials for Leukemia. Search for Leukemia clinical trials in different cities and states across the United States.
Sponsor:
Foghorn Therapeutics Inc.
Location:
Code:
NCT04891757
Conditions
Advanced Hematologic Malignancy
Relapsed Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Relapsed Myelodysplastic Syndromes
Refractory Myelodysplastic Syndromes
Eligibility Criteria
Sex: All
Age: 16+
Healthy Volunteers: Not accepted
Interventions
FHD-286
Low Dose Cytarabine
Decitabine
Sponsor:
Genmab
Location:
Code:
NCT05206357
Conditions
Non-hodgkin Lymphoma
Eligibility Criteria
Sex: All
Age: 1 - 25
Healthy Volunteers: Not accepted
Interventions
Epcoritamab
Sponsor:
M.D. Anderson Cancer Center
Location:
Code:
NCT01371630
Conditions
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Burkitt-Like Lymphoma With 11q Aberration
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
High Grade B-Cell Lymphoma, Not Otherwise Specified
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Blinatumomab
Cyclophosphamide
Cytarabine
Dexamethasone
Inotuzumab Ozogamicin
Sponsor:
M.D. Anderson Cancer Center
Location:
Code:
NCT05115630
Conditions
Myeloid Malignancies
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Chronic Myeloid Leukemia
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
Cyclophosphamide
Mesna
Filgrastim
Melphalan
Fludarabine phosphate
Sponsor:
Children's Hospital Medical Center, Cincinnati
Location:
Code:
NCT02143830
Conditions
Fanconi Anemia
Severe Marrow Failure
Myelodysplastic Syndrome (MDS)
Acute Myelogenous Leukemia (AML)
Eligibility Criteria
Sex: All
Age: 3+
Healthy Volunteers: Not accepted
Interventions
Busulfan
Cyclophosphamide
Fludarabine
rabbit ATG
G-CSF
Sponsor:
BeiGene
Location:
Code:
NCT04771130
Conditions
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasm
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BGB-11417
Azacitidine
Posaconazole
Sponsor:
Dren Bio
Location:
Code:
NCT05475925
Conditions
LGLL - Large Granular Lymphocytic Leukemia
Primary Cutaneous T-Cell Lymphoma - Category
Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma
Hepatosplenic T-cell Lymphoma
Subcutaneous Panniculitis-Like T-Cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
DR-01
Sponsor:
Mayo Clinic
Location:
Code:
NCT06151730
Conditions
Chronic Lymphocytic Leukemia
Hematopoietic and Lymphoid System Neoplasm
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Waldenstrom Macroglobulinemia
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Non-Interventional Study
Sponsor:
Dana-Farber Cancer Institute
Location:
Code:
NCT05168930
Conditions
Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Venetoclax
Zanubrutinib
Sponsor:
Prelude Therapeutics
Location:
Code:
NCT05665530
Conditions
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Mantle Cell Lymphoma (MCL)
Richter's Syndrome
T-cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
PRT2527
Zanubrutinib
Venetoclax
Clinical trials for leukemia are research studies designed to evaluate new treatments, therapies, or diagnostic methods for different types of leukemia, a group of cancers that affect the blood and bone marrow. These trials aim to discover more effective ways to treat leukemia, manage its symptoms, and improve patient outcomes. They may involve testing new drugs, combinations of existing treatments, targeted therapies, immunotherapies, or novel approaches like gene therapy.
Leukemia clinical trials are crucial because they drive advancements in treatment by testing new therapies, improving existing ones, and exploring novel approaches to manage and potentially cure the disease. These trials provide essential data on the safety and effectiveness of new treatments, which can lead to better outcomes and fewer side effects compared to current options.
Researchers have a number of options available when it comes to choosing the type of clinical trial that should be used for a leukemia research study.
Diagnostic trials in leukemia clinical research focus on developing or refining techniques for detecting and diagnosing the disease more accurately and earlier. These trials test new diagnostic tools, such as imaging technologies, blood tests, or genetic assays, to improve the precision of leukemia detection, identify specific subtypes, and monitor disease progression.
By enhancing diagnostic methods, these trials aim to enable earlier intervention, tailor treatments more effectively, and ultimately improve patient outcomes and survival rates.
Genetic and biomarker studies in leukemia focus on identifying specific genetic mutations, variations, and molecular markers associated with the disease. By analyzing the genetic profile of leukemia cells and patients, researchers can uncover the underlying mechanisms that drive the disease's development and progression. This information is crucial for advancing personalized medicine, as it enables healthcare providers to tailor treatments to the unique genetic makeup of each patient.
Interventional trials for leukemia actively test new treatments or therapeutic approaches by administering experimental drugs or therapies to participants. These trials evaluate the effectiveness and safety of new drugs, compare new treatments with standard options, explore combination therapies, and assess innovative strategies like stem cell transplants or gene therapy. They also help determine optimal dosages and administration schedules.
Researchers can use prevention trials for leukemia to identify strategies to reduce the risk of developing the disease or to prevent its recurrence in patients who are in remission. These trials may test interventions such as medications, lifestyle changes, or vaccines in individuals at high risk for leukemia, such as those with a family history or predisposing conditions.
By evaluating these preventive measures, the trials seek to find effective ways to lower the incidence of leukemia or delay its onset, ultimately improving long-term outcomes and quality of life for those at risk.
Just as many clinical trials can pose risks or considerations, leukemia clinical trials can offer a number of benefits for participants too.
Participating in a clinical trial for leukemia offers several benefits, including access to cutting-edge treatments and therapies that may not be available outside the trial. Participants receive close monitoring and care from specialized medical teams, which can lead to early detection of side effects and more personalized treatment adjustments.
Leukemia clinical trials also contribute to valuable research, advancing medical knowledge and supporting the development of better future treatments. Additionally, involvement in a trial provides an opportunity to potentially benefit from new interventions that could improve outcomes and quality of life.
When deciding whether to participate in a clinical trial for leukemia, it’s important to think about the risks and considerations, such as the potential for unknown side effects from experimental treatments, which may be worse or different from standard therapies. There is also the risk that the new treatment may not be effective, potentially leading to a lack of improvement or worsening of the condition.
Participants might also face rigorous schedules for medical visits and tests, which can be time consuming and inconvenient. It’s possible that participants could have uncertainties about coverage of trial-related expenses, as well as the emotional stress of navigating an experimental treatment.
Worried about the risks of participating in a clinical trial? Delve into our comprehensive guide to gain insights into the potential outcomes of participating. Learn about potential risks, benefits, and safety considerations to make an informed decision about your participation in a clinical trial.
Specific criteria for involvement in a leukemia clinical trial depends on the trial’s objectives and design, but researchers often include factors such as the type and stage of leukemia, overall health, and prior treatments. Some trials may focus on particular age groups, such as children or adults, while others might target specific genetic mutations or risk factors. For most leukemia clinical trials, a leukemia diagnosis or a high risk of developing it is usually the first requirement.
In addition to patients with active leukemia, some trials may also include healthy volunteers for comparison purposes or individuals in remission to test preventive measures or recurrence interventions.
When participating in a clinical trial for leukemia, you can expect to undergo a detailed screening process to confirm eligibility and provide informed consent about the study's purpose, procedures, risks, and benefits. You may receive experimental treatments or therapies, and will be closely monitored through regular medical visits, tests, and assessments to evaluate the effectiveness and safety of the intervention.
The trial may involve strict protocols, including rigorous schedules and adherence to treatment regimens. While participation in a leukemia clinical trial potentially offers access to innovative treatments and specialized care, it also involves the potential for unknown side effects and uncertainties regarding treatment outcomes.
Enrolling in a clinical trial studying leukemia through our platform is a straightforward and user-friendly process. Here's how to get started: